The Illinois Department of Healthcare and Family Services (HFS) has just filed its initial report in response to an executive order, bringing some hope to the sickle cell community. The advisory council, as assigned by the Governor, focused on ironing out the financial wrinkles to make gene and cell therapy treatments more accessible and affordable to Illinois residents, especially for those insured by state Medicaid programs. This was not only an administrative due diligence but a crucial stride toward equity in healthcare.
Amidst the Healthcare landscape's evolution, which is promising yet pricey with treatments easily going over a million dollars per patient, equitable access to care stands as a daunting challenge. "The ability to address debilitating diseases at their root cause has the potential to change patient's lives in ways that were previously unimaginable," Dr. James LaBelle, Director of the Pediatric Stem Cell and Cellular Therapy Program at the University of Chicago, told the Illinois Government News Network, emphasizing the importance of biology over socio-economic barriers in healthcare access.
Governor JB Pritzker's administration is looking to the advisory council's report to devise a way forward. "When I signed the Executive Order to create this council, it was with the clear goal of making life-changing gene and cell therapy treatments affordable and available to every Illinoisan," Governor Pritzker said in a statement. The recommendations look at various value and outcome-based payment approaches, gauging successes and setbacks from other states' experiences, to chart a course for Illinois.
The issues faced by patients, especially with rare diseases, are numerous and complex, with barriers ranging from provider shortages to geographical access. Recommendations have been split into three key areas: financing cell and gene therapies, ensuring equitable access, and additional considerations impacting finance and access sequence. With a move to join the federal Cell and Gene Therapy (CGT) Access Model being initiated by CMS, the state also aims to tackle financial risks and hopes to enlist expert help to carry out these strategies.
Reflecting the collective voice, Executive Director of the Sickle Cell Disease Association of Illinois, TaLana Hughes, MPH, acknowledged the Council's effort and the importance of their time-sensitive task. In robust debates, stakeholders carved out strategies that they believe "supports equitable access while contributing to a much larger national effort to formulate solutions," Hughes said. These measures include evaluating the federal CGT Access model for potential added benefits and cost reductions for the state's Medicaid patients.
